Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say
Higher blood levels of omega-3 fatty acids, fatty molecules found in food and shown to have health benefits, significantly associate with a lower risk of…
Katherine Poinsatte, PhD, — 
Articles by Katherine Poinsatte
Study fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
Excessive copper in PFIC3 may lead to misdiagnosis: Case report
Excessive copper levels in the body led to an initial misdiagnosis of Wilson disease, a rare condition marked by copper buildup in the liver and…
New ABCB11 mutation linked to PFIC2, hypothyroidism in boy
A new ABCB11 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 2 (PFIC2) in a boy who was also born with…
Survodutide wins breakthrough therapy for fatty liver disease
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…
FDA gives denifanstat for MASH breakthrough therapy status
The U.S. Food and Drug Administration (FDA) has given breakthrough therapy designation to denifanstat, Sagimet Biosciences’ investigational oral therapy for metabolic dysfunction-associated steatohepatitis…
New ABCB4 mutation deemed cause of PFIC3 in 2 unrelated girls
A new ABCB4 gene mutation was the likely cause of progressive familial intrahepatic cholestasis type 3 (PFIC3) in two unrelated Southeast Asian girls, a study…
New PLEC gene mutations are likely cause of girls’ liver ailment PFIC
Scientists in Thailand have identified four new mutations in the PLEC gene as the likely cause of progressive familial intrahepatic cholestasis (PFIC) in two…
Orsini, Pantherx pharmacies will dispense Livdelzi for PBC in US
Specialty pharmacy services for Livdelzi (seladelpar), the newly approved second-line therapy for adults with primary biliary cholangitis (PBC), will be provided in the U.S.